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Abstract
Neurofibromatosis type 2 (NF2) is an inherited tumor predisposition syndrome 
leading to the formation of vestibular schwannomas (VS) and other central nervous 
system (CNS) tumors. Clinical NF2 follows a genetic alteration to the NF2 gene, 
which disrupts the function of a cell membrane-related protein, merlin. Though the 
role of merlin is incompletely understood, it is predominantly thought to achieve 
tumor suppressive effects by affecting multiple signaling pathways important for 
contact inhibition, cellular proliferation, and cellular growth. Patients with NF2 
have a bimodal age of onset in children and young adults, with the former tending 
to present with a more severe phenotype involving multiple tumors. Currently 
available treatments are non-curative. Surgical resection is the mainstay for grow-
ing tumors but comes at the cost of significant morbidity, while radiotherapy is 
generally not advisable due to the risk of secondary malignancy and malignant 
transformation. Hence, there remains a critical demand for effective anti-neoplastic 
therapies for NF2-related tumors. There are currently no FDA-approved biologic 
therapies for the treatment of NF2. Given the complexity and far-reaching effects 
of Merlin, multiple molecular targets and pathways have been investigated and are 
currently at various stages of investigation.
Keywords: neurofibromatosis type 2, Merlin, vestibular schwannoma,  
targeted therapy, Bevacizumab, axitinib, sorafenib, lapatinib, erlotinib, crizotinib, 
brigatinib, everolimus, vistusertib, AR-42, selumetinib
1. Introduction
NF2 is an autosomal dominant, tumor predisposition syndrome with an inci-
dence of 1:25,000–1:40,000 [1, 2]. The diagnosis is made based on the presence 
of specific clinical features. Under the NIH criteria, a patient can be diagnosed 
with NF2 if they have [1] bilateral VS or [2] have a family history significant for 
NF2 and any one of the following: unilateral VS, other schwannoma, meningioma, 
glioma, neurofibroma, or juvenile posterior subscapular lens opacity [3]. Notably, 
the presence of a pathogenically mutated NF2 gene is not necessary to complete the 
diagnosis.
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The NF2 gene is located on the long arm of chromosome 22, and encodes for the 
cell membrane-related protein, Merlin or Schwannomin. Though the function of 
Merlin is incompletely understood, it is predominantly thought to achieve tumor 
suppressive effects by affecting multiple signaling pathways important for contact 
inhibition, cellular proliferation, and cellular growth [4, 5]. A wide variety of 
genetic alterations affect the gene predisposing to NF2, including frameshift, non-
sense, missense, and less commonly, splice site [6, 7]. Mutations of the NF2 gene 
are only detected in 70% of affected patients, and the rate of detection is even less 
for patients without a family history. This discrepancy is explained by mosaicism: 
about 25–30% of NF2 patients with a de novo mutation of the NF2 gene are mosa-
ics, where only a portion of their cells contain the mutated gene [8].
Patients with NF2 are prone to develop multisystemic clinical features involv-
ing the nervous system, eyes, and skin. The most common clinical manifestations 
include bilateral VS, intracranial and spinal tumors (other schwannomas, meningi-
omas, and ependymomas), peripheral neuropathy, cataracts, and cutaneous tumors 
[9, 10]. Less common but prevalent features include epiretinal membranes, retinal 
hamartomas, skin plaques, and subcutaneous tumors [9, 10].
The age at clinical onset is bimodal: the first peak is in children, with a median 
age of onset ranging from 8 to 14 years in pediatric patients [11–13], while the 
second is between the ages of 20 and 22 for adults [9, 10]. Correspondingly, the 
clinical presentation of patients affected by NF2 is grouped into two main subtypes: 
the more aggressive Wishart type, more common for childhood-onset, and the less 
aggressive Gardner type, presenting in adulthood [13]. Adults tend to present with 
symptoms of tinnitus, hearing loss, and/or imbalance related to VS, while children 
have a higher likelihood of presenting with symptoms due to spinal cord compres-
sion or other CNS-tumors, as well as ophthalmologic involvement [11, 12, 14].
Growth rates for NF2-related tumors vary [15]. Although NF2-related VS are gen-
erally slow growing, they are known to cause considerable morbidity and mortality. 
Left untreated VS leads to decline in auditory function and complete hearing loss over 
a period of several years [16]. The goal of treatments for NF2 is to reduce the presence 
of disabling symptoms, and help improve overall survival for patients. Unfortunately, 
there are no FDA-approved pharmacologic therapies, and currently available treat-
ment options are non-curative. Surgical resection remains the only approved and 
standard treatment for NF2-related tumors, while radiotherapy is a less desirable 
option. Targeted biologic therapies may be an emergent treatment option.
Surgical resection is indicated for VS with accelerated growth rate, ≥3 cm in size, 
and/or symptoms of radiographic evidence due to compression of adjacent struc-
tures [17]. However, surgical intervention comes at the risk of hearing loss, facial 
paralysis, damage of lower cranial nerves, stroke, and CSF leak [17]. In addition, 
VS can recur following resection: a large retrospective review evaluating 148 NF2 
patients with a mean pre-operative tumor size of 3.1 cm and a mean follow-up of 
12 years revealed a recurrence rate of 14% [18]. The size of VS also does not corre-
late with the degree of hearing loss [19, 20], and at times there is profound hearing 
loss despite a very small size of the VS where surgical resection would unlikely 
reverse deafness. In contrast to VS, other schwannomas tend to be slower growing 
and hence surveillance with serial imaging is recommended; surgical resection is 
reserved for tumors symptomatically affecting the patient [17].
In regards to NF2-related meningiomas, surgical resection is advised when 
patients become symptomatic or tumors demonstrate increased growth rate [10, 17]. 
In contrast, the role of surgical resection for spinal ependymomas is not clearly estab-
lished. Results from a multi-institutional retrospective review suggest that timely 
resection in the hands of a skilled neurosurgeon may improve a patients’ natural 
clinical history [21].
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NF2-related tumors may also be treated with radiotherapy. There is no formal 
consensus regarding the role of radiotherapy for NF2 patients with growing 
VS. The use of external beam radiotherapy for progressive VS in NF2 patients is 
considered controversial due to the increased risk of malignant transformation 
and secondary malignancy, as compared with patients with sporadic VS [22–24]. 
Additionally, patients with NF2-related progressive VS treated with radiotherapy 
have poorer rates of local control and reduced preservation of hearing as com-
pared with non-NF2 patients [17, 25]. In a large retrospective study by Rowe 
et al., only 40% of 92 NF2 patients with growing VS treated with stereotactic 
radiosurgery (SRS) retained hearing function at 3 years post treatment; the rest 
progressed, including 20% of patients who developed complete hearing loss [26]. 
Overall, radiotherapy for NF2-related VS is not recommended, and is reserved 
for surgically inaccessible tumors [3]. Moreover, radiotherapy prior to surgical 
resection has fallen out of favor due to the observation that radiotherapy makes 
resection of VS more difficult [3]. Data on SRS for NF2-related meningioma is 
even more scarce. In general, radiation therapy is not advised due to the risk of 
creating a secondary malignancy, and is reserved for atypical and/or anaplastic 
meningiomas [17].
2. Biologically targeted therapies
Current treatment options for NF2-related tumors provide only temporary 
benefits and there are no FDA-approved pharmacologic therapies for NF2. There 
remains an unmet need for effective anti-neoplastic therapy of NF2-related tumors. 
Since NF2-related tumors tend to be slow growing, options such as cytotoxic 
chemotherapies are not appropriate to treat this lifelong condition, thus molecularly 
targeted therapies represent a better treatment modality and a budding and encour-
aging prospect.
Merlin is a multifunctional protein that is involved with the regulation of intra- 
and extracellular molecules and biologic pathways that are important for cellular 
structure, survival, proliferation, and contact-dependent inhibition. Increased 
research efforts have enabled the discovery of various molecular pathways and 
targets relevant to the pathogenesis of NF2-related tumors. These include vascu-
lar endothelial growth factor (VEGF), platelet-derived growth factor receptor 
(PDGFR), and epidermal growth factor receptor (EGFR), phosphoinositide 
3-kinase (PI3K)/Akt, histone deacetylase (HDAC), and mammalian inhibitor 
of rapamycin (mTOR). The mechanisms of these targets and their pathways are 
briefly discussed here.
NF2-VS have increased expression of VEGF [27, 28], a powerful mediator of 
tumor angiogenesis [29]. Additionally, VS are highly vascular tumors, making anti-
angiogenesis an appealing option that has been evaluated in NF2 patients in clinical 
studies [30] and is described in further detail in Section 2.1. The precise mechanism 
of angiogenesis regulation by Merlin is not known, but a downstream pathway 
implicating the Rac1 GTPase has been described [31]. Merlin is thought to maintain 
angiogenesis by regulating Rac1 activity. In NF2-deficient Schwann cells, increased 
Rac1 activity lead to augmented VEGF levels and more tumor burden [31].
Another growth factor relevant to NF2-pathogenesis is PDGFR. PDGFR accu-
mulates on the surface of NF2-deficient Schwann cells [32, 33]. Increased activation 
of PDGFR leads to downstream phosphorylation of B-catenin, and subsequent 
destabilization of cell junctions, loss of contact-dependent inhibition, and 
increased cell cycle activity [32]. Intact Merlin is important for regulating the con-
centration of cell surface PDGFR through degradation pathways [34]. In preclinical 
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studies, inhibitors of PDGFR reduced proliferation of NF2-deficient Schwann cells 
via negative regulation of ERK and Akt [35].
The ErbB family of receptor tyrosine kinases has also been increasingly studied 
in NF2, primarily ErbB1 (EGFR). NF2-deficient cells have increased levels of EGFR 
[32, 33], leading to increased cellular proliferation and resistance to apoptosis [36]. 
Merlin can physically associate with and negatively regulate EGFR by controlling 
its membrane distribution and subsequent trafficking [37–39], thereby blocking 
various downstream targets including Raf, extracellular signal-regulated kinase 
(ERK), and Akt [32]. Moreover, pharmacologic inhibitors of EGFR efficiently 
revert the phenotypic consequences of NF2-deficiency in several types of cultured 
cells [37–39].
Merlin is also involved in regulating a number of pathways and intracellular 
targets relevant to cellular proliferation and survival. In NF2 preclinical studies, 
loss of merlin activity leads to Schwann cell growth via activation of the PI3K/Akt 
pathway [40, 41]. Normally, Merlin inhibits PI3K activity, preventing downstream 
phosphorylation and hence activation of Akt, a protein kinase responsible for 
proteasome-mediated degradation of Merlin [42]. Akt phosphorylation is also 
regulated by HDAC; pharmacologic inhibitors of HDAC lead to tumor shrinkage 
and inhibition of cellular growth in preclinical NF2 studies [43].
In addition, gene-expression profiling of sporadic and NF2-associated VS 
demonstrated overexpression of the PI3K/Akt/mTOR pathway [44]. MTOR 
complex 1 (mTORC1) is an evolutionarily conserved protein kinase involved with 
cell survival, metabolism, and protein translation [45]. In contrast, mTOR com-
plex 2 (MTORC2) regulates the actin cytoskeleton and activation of Akt [45, 46]. 
Merlin is considered a negative regulator of mTOR. Loss of Merlin function leads 
to constitutive mTOR signaling in NF2-deficient tumors, including schwannomas, 
meningiomas, and mesotheliomas. Notably, aberrant signaling of mTOR in NF2-
tumorigenesis is independent of PI3K/Akt pathways [45]. In preclinical studies, 
inhibition with mTORC1 reversed the phenotypic consequences of NF2-deficient 
schwannoma and meningioma cell lines [45, 47].
In the following sections, specific pharmacologic-targeted therapies and rel-
evant clinical studies are discussed further.
2.1 Angiogenesis inhibitors
2.1.1 Bevacizumab
The use of Bevacizumab, a humanized monoclonal antibody targeting VEGF, 
has resulted in meaningful imaging and hearing response rates for NF2 patients 
with progressive VS [28, 48, 49]. Plotkin et al. first showed the intravenous admin-
istration of Bevacizumab at 5 mg/kg every 2 weeks resulted in tumor reduction in 9 
out of 10 patients, with an imaging response in 6 out of 10 patients, and improved 
or stabilized hearing (as measured by word-recognition scores) in 6 out of 7 eligible 
patients [28]. Additional studies with larger patient cohorts have demonstrated 
imaging and hearing response rates of 39–55% and 45–57%, respectively [48, 49], 
in addition to improved quality of life [49]. The average time to treatment response 
was 3 months [48, 49]. Hearing remained stable or improved in 86–90% of patients 
after 1 year [48, 49] and 61% after 3 years [48]; tumor volume remained stable or 
reduced in 88–90% of patients after 1 year and 54–63% after 3 years [48, 49]. In a 
large multi-institution prospective study with 51 NF2 patients, predictors of imag-
ing response included older age: 6 patients <18 years with evaluable VS exhibited 
significantly reduced responses to Bevacizumab and tended to have faster growing 
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tumors refractory to treatment, as compared with their adult counterparts [49]. 
Similarly, a small retrospective study evaluating the efficacy of Bevacizumab for 
pediatric NF2 patients with progressive VS also yielded poor results: none of the 
seven patients met criteria for a radiographic response, and of the four evaluable 
patients for hearing assessments, one improved while three stabilized [50]. These 
observations are in line with previous studies revealing that younger patients have 
a higher likelihood of developing more severe phenotypes with accelerated tumor 
growth rates [15, 51].
This constellation of clinical results for adult and pediatric NF2 patients lead 
to phase II clinical studies evaluating the effect of bevacizumab for NF2 patients 
with growing VS. In the phase II study by the National Cancer Institute, a dose of 
bevacizumab 7.5 mg/kg every 3 weeks for 12 months was administered, the results 
of which are pending (NCT01207687). In the study by Plotkin et al., patients were 
treated with bevacizumab 10 mg/kg every 2 weeks for 24 weeks, followed by 5 mg/
kg every 3 weeks [30]. Published preliminary results showed that 22 patients with 
NF2-related progressive VS experienced tumor shrinkage and improved hearing 
in 43 and 36% of patients, respectively [30]. In line with past studies [49, 50], the 
seven NF2 patients ≤21 years had much less benefit as compared with patients 
>21 years [30]. In fact, only one out of seven demonstrated a hearing response, and 
no patients had a radiographic response [30]. Reported adverse events were similar 
to prior studies [48, 49], and included hypertension, proteinuria, delayed wound 
healing, fatigue and irregular menses [30].
Unfortunately, the presence of these adverse events can lead to interruptions 
and even discontinuation of Bevacizumab therapy. In addition, long-term therapy 
with Bevacizumab is also limited by cumulative toxicities: primarily hypertension 
and proteinuria, but also, premature ovarian insufficiency in menstruating females. 
Responses are not sustained off treatment and discontinuation of Bevacizumab has 
been associated with accelerated VS regrowth and decline of hearing function [48]. 
The optimal duration of therapy with Bevacizumab for NF2-related VS remains 
unknown.
Bevacizumab has also been administered for treatment of other NF2-related 
tumors, including meningiomas and ependymomas. In a small retrospective study 
involving 15 patients with NF2-related meningiomas, a volumetric response rate of 
29% was observed, however the median duration of response was limited at only 
3.7 months [52]. Hence the effectivity for Bevacizumab in treating NF2-related 
meningioma remains unclear. In regards to NF2-related ependymoma, a retrospec-
tive evaluation demonstrated no significant benefit for patients with solid ependy-
momas, however, 7 out of 12 patients who had ependymomas with a syrinx or cystic 
component demonstrated radiographic and clinical improvements in response to 
treatment with Bevacizumab [53].
2.1.2 Axitinib
Axitinib is an orally available small molecule multikinase inhibitor of VEGF, 
PDGFR, and c-KIT (a receptor tyrosine kinase), leading to reduction of angiogen-
esis. Preclinical NF2 models have demonstrated the relevance of these molecular 
targets in the pathogenesis of NF2-related schwannomas [35, 54]. Specifically, in 
vitro studies on human schwannoma cells from NF2 patients revealed inhibition 
of PDGFR and c-KIT activation lead to inhibition of schwannoma cell growth and 
induction of schwannoma cell death [35, 54]. Recently, these results have been 
translated into an ongoing phase II clinical trial, evaluating the efficacy of axitinib 
in patients with NF2 and progressive VS (NCT02129647).
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2.1.3 Sorafenib
Sorafenib is an orally available small molecular multikinase inhibitor against 
PDGFR, VEGF, and kinase-Raf1 (C-RAF). The relevance of these markers for VS 
tumorigenesis has been investigated in preclinical studies: increased PDGFR activ-
ity lead to increased cellular proliferation of human schwannoma cells in vitro by 
upregulating ERK 1/2 and Akt [35]. Expectedly, treatment with sorafenib reversed 
the PDGFR-mediated proliferation of schwannoma cells, and decreased the activity 
of ERK 1/2 and Akt [35]. These results were translated into a clinical study assessing 
the intratumoral concentration and activity of sorafenib in cutaneous schwanno-
mas in NF2 patients (ISRCTN49989464), the results of which are pending.
2.1.4 Highlights
• Bevacizumab has efficacy in treating NF2-related VS, as evidenced by tumor 
reduction or stabilization, and improved hearing assessments or clinical 
stabilization [17, 28, 30, 49], in addition to improved quality of life [49].
• The exact dose remains to be determined, variable doses of 5 mg/kg every 
2 weeks, 5 mg/kg every 3 weeks, and 10 mg/kg every 2 weeks have all demon-
strated effectivity [17, 30, 49].
• As compared with their adult counterparts, there is less benefit in the treat-
ment of pediatric NF2-related VS [30, 49].
• Although well tolerated for shorter durations, cumulative toxicities limit the 
long-term use of Bevacizumab, and responses are not sustained off treatment 
[48]. Optimal duration of treatment remains unknown.
• Bevacizumab is partially effective in treating NF2-related meningiomas, 
although these responses are not particularly durable [52].
• No benefit has been demonstrated for the treatment of solid ependymomas, 
however, ependymomas with a cystic component or syrinx had a modest 
response rate [53].
• Axitinib and sorafenib have demonstrated anti-schwannoma activity in preclin-
ical studies [35, 54] and have been evaluated in clinical studies (NCT02129647 
and ISRCTN49989464, respectively), the results of which are pending.
2.2 Tyrosine kinase inhibitors
2.2.1 Lapatinib
Lapatinib is an orally active small molecule, reversible tyrosine kinase inhibitor 
of EGFR and human epidermal growth factor receptor 2 (HER2/neu). Preclinical 
studies showed lapatinib had anti-proliferative effects on human schwannoma 
cells from NF2 patients in vitro, via downregulation of ERBB2, survivin, and other 
downstream receptor kinases [55]. Subsequently, in a phase 2 clinical trial for adults 
and children with NF2 and progressive VS, treatment with lapatinib resulted in 
imaging and hearing responses in 4 out of 17 patients and 4 out of 13 evaluable 
patients, respectively [56]. However, audiological responses were sustained in 
only one patient, and persisted for 9 months [56]. Based on these results, the 2018 
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Congress of Neurological Surgeons suggested there is Level 3 evidence to support 
lapatinib monotherapy in reducing VS volume and/or improving hearing function 
in NF2 patients with VS [57].
In addition, the effect of lapatinib on meningioma growth was evaluated in 
NF2 patients who received lapatinib in the clinical study described above [58]. 
Eight out of 17 patients had a total of 17 volumetrically measurable meningiomas 
and received at least 5 cycles of lapatinib [58]. Increased meningioma growth was 
observed in patients off lapatinib therapy (9 out of 17), as compared with those 
on treatment (2 out of 17). One patient had significant volume shrinkage which 
sustained for 23 months on lapatinib [58]. Hence, lapatinib may reduce the growth 
rate of NF2-related meningiomas and delay time to progression [58].
In regards to toxicity, in general treatment was tolerable and the most common 
adverse events were minor including most commonly skin rash, and less commonly 
fatigue, headache, diarrhea, nail changes, and elevations of liver transaminases 
without impact on liver function [56]. One patient developed a grade 3 toxicity 
of delayed wound healing postoperatively, and no grade 4 or 5 toxicities were 
observed [56].
2.2.2 Erlotinib
In contrast to lapatinib’s pan-Erb inhibitory activity, Erlotinib is an orally active 
tyrosine kinase inhibitor that is selective for EGFR. Preclinical studies demon-
strated persistent EGFR signaling in NF2-deficient cells contributes to cellular 
proliferation, and that treatment with a selective EGFR inhibitor stopped cellular 
proliferation at a high cell density via contact-dependent inhibition [37].
In a retrospective study, 11 patients with NF2-related progressive VS ineligible 
for surgical resection or radiotherapy were treated with erlotinib on the basis of 
compassionate use [59]. Unfortunately, no significant imaging or hearing responses 
were observed, though median time to clinical progression was 9.2 months [59]. 
Notably, the subset of four evaluable patients reported to experience stable disease 
on erlotinib all had slow VS growth rates (baseline annual volumetric growth rate 
ranging from 6 to 14%) prior to erlotinib initiation [59]. In summation, erlotinib is 
not effective in treating fast growing VS, however it may delay time to progression 
in patients with slow growing VS. The adverse event profile of erlotinib is similar 
to that of lapatinib, and primarily included minor toxicities of skin rash, diarrhea, 
and hair thinning [59]. Two patients developed a rare corneal keratopathy that was 
related to eyelash curling [59].
2.2.3 Crizotinib
Crizotinib is an orally active, small molecule multi-target tyrosine kinase 
inhibitor of mesenchymal-epithelial transition (MET), anaplastic lymphoma kinase 
(ALK), and c-ros oncogene 1 (ROS1). In orthotopic mouse models of NF2, treat-
ment with crizotinib resulted in slower growth of VS as compared with those who 
did not receive the drug [60]. Kissil et al. found that wildtype focal adhesion kinase 
(FAK1) was necessary for proliferation of NF2-null Schwann cells and treatment 
with crizotinib lead to inhibition of FAK1 and significantly reduced proliferation of 
NF2-null Schwann cells [60]. Conversely, treatment with crizotinib-resistant forms 
of FAK1 reversed the anti-proliferative benefits seen with wildtype FAK1 [60]. 
Hence, the primary anti-proliferative activity of crizotinib on NF2-null Schwann 
cells is mediated through inhibition of FAK1 [60]. FAK has previously been recog-
nized as a target involved with NF2-mediated tumorigenesis [61]. In addition, MET 
has also been implicated in the pathogenesis of NF2-related VS [62, 63]. Recently, 
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these results have been translated into an upcoming phase II clinical trial evaluating 
the efficacy of Crizotinib in children and adults with NF2 and progressive VS, set to 
open for enrollment later this year.
2.2.4 Brigatinib
Brigatinib is an orally available, small molecule tyrosine kinase inhibitor of 
ALK and EGFR. Based on a cell viability screen, ALK was identified as a promising 
target for inhibiting growth of NF2-deficient Schwann cells [64]. Subsequently, 
administration of brigatinib to NF2 mouse models delayed growth of schwannomas 
and better preserved hearing, as compared with vehicle-treated models [64]. These 
results have contributed to the development of a phase II clinical study for NF2 
patients, which is currently being developed and set to open for enrollment later 
this year.
2.2.5 Highlights
• Lapatinib has modest effect in reducing VS volume and/or improving hearing 
function in NF2 patients with VS [56, 57]
• Erlotinib is not effective in shrinking VS or improving hearing function, how-
ever, it may delay time to progression in patients with slow growing VS [59].
• Crizotinib and Brigatinib have demonstrated anti-schwannoma activity in 
preclinical studies and these results have been translated into a phase II clinical 
studies set to open later this year.
2.3 Mammalian target of Rapamycin (mTOR) inhibitors
2.3.1 Everolimus (RAD001)
Everolimus is an orally available inhibitor of mTOR complex 1 (mTORC1). 
Merlin is considered a negative regulator of mTORC1, and loss of merlin function 
leads to increased mTOR signaling and NF2-related tumorigenesis [65]. In preclini-
cal studies, inhibition of mTORC1 with rapamycin lead to VS tumor shrinkage in 
vivo [47] and halted growth of NF2-deficient meningioma cells in vitro [45]. These 
results were subsequently translated into two phase II clinical trials evaluating the 
efficacy of everolimus in NF2 patients with progressive VS [66, 67]. Both trials 
included adult and pediatric NF2 patients and subjects were treated with everolimus 
at 10 mg/day for continuous 28-day cycles. Neither study demonstrated any appre-
ciable tumor shrinkage or hearing improvement after treatment with everolimus 
[66, 67]. However, in the phase II study by Karajannis et al., three adult patients did 
experience mild reductions in their target VS (−3.6 to −11.93 cm3 reduction from 
baseline); two of these patients discontinued treatment at 3 and 6 months due to 
personal preference, while the third continued for 12 months with stabilization 
of their index VS [67]. Goutagny et al. also found that treatment with everolimus 
resulted in stabilization of tumor volumes, as well as hearing function, in five out 
of nine evaluable adult patients [66]. Stabilization was parallel to a decrease in the 
median annual growth rate of VS, from 67% per year before treatment to 0.5% per 
year during treatment [66]. Overall, time to tumor progression also increased, from 
4.2 months before treatments to >12 months with treatment [66].
In the five patients with stabilization of disease on everolimus, discontinua-
tion after 12 months lead to rebound effects on tumor growth rate [66]. All five 
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patients experienced marked growth of VS volumes 2–6 months after discontinu-
ation; one patient had concomitant decline of hearing and balance and elected 
to undergo surgical resection [66]. In the other four patients, resumption of 
everolimus leads to a median VS volume reduction of 6.8% at 24 months and 
increased time to tumor progression [68]. Thereafter, the study was amended to 
increase duration of therapy with everolimus for another 2 years [68]. At 4-year 
follow-up, one patient continued to remain stable on everolimus, and the other 
three patients progressed radiographically after 36, 39, and 45 months of treat-
ment; hearing function was stable for three out of four patients [68]. Hence, 
reintroduction of everolimus resulted in delayed time to progression from a 
median of 2.9 months before treatment, to 13.9 months with treatment [68]. In 
addition, the previously observed rebound effect on VS growth rate following 
withdrawal of everolimus, did not occur with discontinuation of therapy after VS 
progression on treatment [68]. Two of the three patients with progression went 
on to receive bevacizumab, which resulted in tumor shrinkage for one patient 
and stabilization for the other [68].
Notably, the patients in the study by Goutagny et al. had received less prior 
medical therapies as compared with Karajannis et al., potentially reflecting a 
less refractory group of NF2-related VS. No rebound effects were observed by 
Karajannis et al., however, as seven out of nine patients were previously treated 
with lapatinib and/or bevacizumab, these therapies may lead to genetic alterations 
of VS tumorigenesis prior to everolimus therapy [67].
Everolimus monotherapy also resulted in stabilization of meningiomas in NF2 
patients. Two patients with asymptomatic frontal meningiomas had increased time 
to progression of meningioma while on everolimus, from 5.5 and 8.5 months before 
therapy, to 17.3 months and not reached, respectively, after 26 months of treatment 
with everolimus [68].
Overall the side effects due to everolimus were tolerable and mostly minor grade 
1 or 2 events including mouth ulcers, rash, headache, fatigue, cholesterol eleva-
tion, sinusitis, and delayed wound healing [66, 67]. One patient developed a grade 
3 toxicity of basocellular carcinoma which did not require additional treatment 
beyond excision [66] and another had transient azoospermia which resolved after 
drug discontinuation [67].
2.3.2 Vistusertib (AZD2014)
AZD2014 is an orally available dual inhibitor of mTOR complex 1 and 2 
(mTORC1/2). Plotkin et al. found that combined mTORC1/2 inhibition was more 
effective than single mTORC1 inhibition in reducing proliferation of NF2-deficient 
meningioma cells in vitro [69]. These results were translated into a phase II clini-
cal study for NF2 patients with growing or symptomatic meningiomas; the trial 
is active however it is not currently recruiting patients according to cancer.gov 
(NCT02831257).
2.3.3 Highlights
• Everolimus is effective in stabilizing VS and delaying time to tumor progression 
in about 50% of patients [66]; these observations are more notable for patients 
who have not been previously treated with other biologic agents [66, 67].
• Early discontinuation of everolimus in patients’ with stable disease may result 
in a life-threatening rebound effect on VS growth rate [66] which can be 
rescued by reintroduction of everolimus [68].
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• Notably, this rebound effect was not observed in patients who progressed on 
everolimus [68] or who had been previously treated with lapatinib or beva-
cizumab [66]. Hence discontinuation of everolimus in setting of ongoing VS 
stabilization is not recommended [68].
• While the timing of everolimus administration remains unclear, data suggest 
it is more likely to achieve tumor stabilization prior to other biologic agents 
[66, 67], and that bevacizumab can be safely administered after progression on 
everolimus with some stabilization of VS [68].
• Everolimus can also slow the growth of meningiomas in NF2 patients [68].
• Vistusertib is a dual mTORC1/2 inhibitor and may have more anti-meningioma 
activity than mTORC1 inhibitors [69]; it is currently being evaluated in a phase 
II clinical study (NCT02831257).
2.4 Histone deacetylase (HDAC) inhibitors
2.4.1 AR-42
AR-42 is an orally active inhibitor of HDAC with multiple downstream molecu-
lar targets, including downregulation of phosphorylated-Akt [70], a protein kinase 
important for cellular apoptosis. Preclinical studies with AR-42 on schwannoma 
and meningioma cells in vitro demonstrated a dose-dependent inhibitory effect on 
the cellular proliferation and increased cellular apoptosis, by reducing Akt activa-
tion [43]. Subsequently these findings were replicated in schwannoma mice xeno-
graft models, which demonstrated the mice that ate AR-42 had 42% smaller tumor 
volume and less phosphorylated-Akt as compared with those that did not receive 
drug [43]. Collectively, these studies demonstrate AR-42 has anti-neoplastic activ-
ity against schwannoma and meningioma cells via a dose-dependent suppression of 
phosphorylated-Akt [43]. These results have been translated into a proof of concept 
phase 0 study assessing expression of phosphorylated-Akt of VS and meningiomas 
in adults receiving AR-42 prior to surgical resection (NCT02282917).
2.5 Mitogen-activated protein kinase (MEK) inhibitors
2.5.1 Selumetinib (AZD6244)
Selumetinib is an orally available small molecule inhibitor of MEK 1 and 2. The 
Ras/MEK/extracellular signal-related kinase (ERK) pathway is implicated in NF2 
tumorigenesis and is strongly activated in NF2-deficient schwannoma cell lines 
[71]. In preclinical studies, inhibition of MEK 1 and 2 with selumetinib lead to ces-
sation of cellular proliferation of human schwannoma cells in vitro and interruption 
of PDFGR-mediated ERK activation [72]. These findings lead to phase II clinical 
study assessing the efficacy of selumetinib for patients with NF2-related tumors, 
and are actively recruiting according to clinicaltrials.gov (NCT03095248).
3. Conclusions
NF2 is a tumor predisposition syndrome that leads to the formation of VS, 
meningiomas, ependymomas, and a variety of ophthalmologic and cutaneous 
features. The management of NF2-related tumors has primarily been with surgery 
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and radiotherapy. However, surgical resection is associated with considerable 
morbidity, and radiotherapy is increasingly less advised due to the risk of malignant 
transformation and secondary malignancies. Hence, there remains a critical need 
for the treatment of patients with NF2-related tumors.
Biologically targeted therapies are an emerging and promising role. 
Dysfunctioning Merlin underlies NF2-associated tumorigenesis and is a multifunc-
tioning protein intimately involved with molecular targets and pathways important 
for cellular metabolism, structure, proliferation, survival, and contact-dependent 
inhibition. Targets that have been validated in preclinical models and translated into 
clinical trials include VEGF, PDGFR, VEGF, PI3K/Akt, HDAC, mTOR, ALK, and 
Ras/Raf/MEK/ERK. Ongoing studies for patients with NF2-related tumors include 
AR-42, selumetinib, and vistusertib, and two other clinical trials are set to open 
later this year: crizotinib and brigatinib. Currently published results from clinical 
studies suggest bevacizumab, everolimus, and lapatinib have some effectivity in sta-
bilizing NF2-VS and to a lesser degree, NF2-meningiomas. Bevacizumab, especially, 
has the ability to preserve function and prevent hearing loss in NF2 patients with 
progressive VS growth or hearing loss. However, these results are not durable and 
tumor growth eventually occurs. Given the multifunctioning reaches of Merlin, 
and the eventual drug-resistance of NF2-related tumors seen with monotherapy, 
developing a multi-drug regimen may be necessary for reducing the emergence of 
drug-resistant tumor cells, optimizing cell kill, and improving overall survival.
In summary, major advancements in understanding NF2 biology has enabled the 
translation of biologically targeted therapies for NF2-related tumors. Secondarily, 
monotherapy with some agents has resulted in stabilization of disease and clinical 
improvement. However, these results are not sustained off treatment, are limited by 
cumulative toxicities, and unfortunately, eventual growth occurs on monotherapy. 
A multi-drug regimen may be the key to overpowering the multifunctioning 
reaches of Merlin, and developing more efficacious long-term therapies with 
improved survival outcomes for patients with NF2.
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